New research shows that specific types of brain cells become active after brain injuries and exhibit properties similar to those of neural stem cells. Astrocyte plasticity might correlate with the upregulation of the Galectin 3 protein, which may significantly contribute to discovery of additional biomarkers. The study discovered that a specific protein regulates these cells and could be a target for therapy and contribute to development of better treatments options for brain injuries. The loss of neurons, which subsequently causes impairment of brain function, is caused by the onset and progression of neurological disorders, like strokes, spinal cord injuries and neurodegenerative diseases such as Parkinson’s, Alzheimers / Dementia, ALS and MND. Effective treatment options still need to be improved. However, preclinical research has shown a promising response involving reactive astrocytes, a specific type of glial cell, which is a crucial part of the nervous system alongside neurons. Microglia and Glial cells are regarded as a safeguard for neurons, demonstrating the ability to resume cell proliferation, a mechanism essential for protecting the injury-affected brain from invasion by immune cells.^[1]

Differentiation of Mesenchymal Stem Cells to Neuroglia.

Given the importance of astrocyte proliferation, these findings are relevant for understanding how changes in cerebrospinal fluid composition (upregulation of Galectin 3 protein) support the maintenance of astrocyte plasticity in the brain. Identifying Galectin 3 protein as an inducer of astrocyte plasticity has helped discover other biomarkers that offer beneficial modulation inside the injured brain parenchyma. These regulators of astrocyte proliferation after acute injury offer great promise for the future clinical applications of these biomarkers as indicators for detecting a beneficial reaction of glial stem cell therapy or help identify the presence of other cells with stemness potential in an injured patient’s brain ^[5].